Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech Daily Utah.
Press releases published on May 1, 2025
iRhythmは、日本においてZio ECG記録・解析システムとしてZio®長期連続モニタリング サービスを開始し、AIを活用した不整脈検出の進化を推進します。
GlobeNewswire
·
May 1, 2025
日本で「Zio ECG記録・解析システム」として商業的に導入されたiRhythm Zio®長期連続心電図モニタリングサービスは、AIを活用した連続的で中断のない心電図モニタリングを最長14日間提供します。 日本における不整脈の早期かつ正確な検出に対する需要が高まる中、本製品の発売は適切なタイミングです。日本は世界第2位の携帯型／ 装着型心電計市場であり、高齢化に伴い不整脈の有病率が上昇すると予想されています1-3。 サンフランシスコ, May 01, 2025 (GLOBE NEWSWIRE) -- …
Nutanix Announces Date and Conference Call Information for Third Quarter Fiscal Year 2025 Financial Results
GlobeNewswire
·
May 1, 2025
SAN JOSE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Nutanix, Inc. (NASDAQ: NTNX), a leader in hybrid multicloud computing, today announced that it will report its financial results for the third quarter of fiscal year 2025, which ended April 30, 2025, after …
Sutro Biopharma to Participate in Upcoming Investor Conferences
GlobeNewswire
·
May 1, 2025
SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will …
Pulmonx to Present at the Bank of America Securities 2025 Health Care Conference
GlobeNewswire
·
May 1, 2025
REDWOOD CITY, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be presenting at the Bank of America Securities …
iRhythm Technologies Announces First Quarter 2025 Financial Results
GlobeNewswire
·
May 1, 2025
SAN FRANCISCO, May 01, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three …
NextCure Provides Business Update and Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 1, 2025
Dosing cohort 3 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers and plan to initiate backfill cohorts in the second half of 2025 Plan to provide a proof of concept data readout in the first half of 2026 Cash of approximately $55.9 million …
Genelux Corporation to Participate in a Fireside Chat at the Citizens Life Sciences Conference
GlobeNewswire
·
May 1, 2025
WESTLAKE VILLAGE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board, and Matt Pulisic, CFO, will …
Zoom to Release Financial Results for the First Quarter of Fiscal Year 2026
GlobeNewswire
·
May 1, 2025
SAN JOSE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Zoom Communications, Inc. (NASDAQ: ZM) today announced it will release its financial results for the first quarter of fiscal year 2026 on Wednesday, May 21, 2025, after the market closes. A live Zoom …
Draganfly Announces Proposed Public Offering of Common Shares & Warrants
GlobeNewswire
·
May 1, 2025
Saskatoon, SK., May 01, 2025 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8A) (“Draganfly” or the “Company”), a drone solutions, and systems developer, today announced it has commenced an underwritten public offering in the United …
Adaptive Biotechnologies Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 1, 2025
SEATTLE, May 01, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to …
Kura Oncology Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 1, 2025
– NDA submitted in 1Q 2025 for ziftomenib for the treatment of adult patients with relapsed or refractory AML with an NPM1 mutation – – Data from Phase 1b/2 registration-directed trial of ziftomenib selected for oral presentation at ASCO Annual Meeting – – …
OptimizeRx Releases 2025 Environmental, Social, and Governance (ESG) Report
GlobeNewswire
·
May 1, 2025
WALTHAM, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, has …
89bio Reports First Quarter 2025 Financial Results and Corporate Updates
GlobeNewswire
·
May 1, 2025
– Topline histology data from ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials are expected in 1H 2027 and in 2028, respectively; each trial is designed to support accelerated approval to treat patients with metabolic dysfunction-associated …
Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements
GlobeNewswire
·
May 1, 2025
Generated $78.3 million in net product sales of XDEMVY®, an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients Strengthened financial position with approximately $135 million raised in public equity …
GSI Technology, Inc. Reports Fourth Quarter and Fiscal Year 2025 Results
GlobeNewswire
·
May 1, 2025
SUNNYVALE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- GSI Technology, Inc. (NASDAQ: GSIT) today reported financial results for its fourth fiscal quarter and fiscal year ended March 31, 2025. Summary Financial Results Table (in thousands, except per share …
Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations
GlobeNewswire
·
May 1, 2025
- Implementation of cost reduction initiatives to position Pliant for execution of late-stage clinical trials - Pliant will reduce its current workforce by approximately 45% - Closing activities for BEACON-IPF trial ongoing; topline data expected in the …
Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 1, 2025
Company reports $74.1 million in Q1 total revenue, reflecting 61% growth year-over-year IBSRELA net product sales revenue of $44.4 million; XPHOZAH net product sales revenue of $23.4 million Company ends Q1 with $214.0 million in cash, cash equivalents …
Asure Announces First Quarter 2025 Results
GlobeNewswire
·
May 1, 2025
Reports First Quarter 2025 Total Revenues of $34.9 million Recurring Revenues Grew 10% from Prior Year AUSTIN, Texas, May 01, 2025 (GLOBE NEWSWIRE) -- Asure Software, Inc. (“we”, “us”, “our”, “Asure” or the “Company”) (Nasdaq: ASUR), a leading provider of …
Aura Biosciences to Participate in Upcoming Investor Conferences
GlobeNewswire
·
May 1, 2025
BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that members of its senior …
scPharmaceuticals Announces Participation in Three Upcoming Investor Conferences
GlobeNewswire
·
May 1, 2025
BURLINGTON, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that John Tucker, …